Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has been assigned a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $15.40.

FOMX has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $11.00 target price (up from $10.00) on shares of Foamix Pharmaceuticals in a report on Monday, October 21st. Cowen set a $30.00 target price on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a report on Monday, September 23rd. Finally, Zacks Investment Research raised shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 22nd.

FOMX stock opened at $2.79 on Tuesday. The firm has a fifty day moving average price of $3.31 and a 200 day moving average price of $2.90. Foamix Pharmaceuticals has a fifty-two week low of $1.97 and a fifty-two week high of $4.48. The company has a debt-to-equity ratio of 0.24, a current ratio of 5.72 and a quick ratio of 5.72.

Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its earnings results on Monday, November 11th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). Foamix Pharmaceuticals had a negative net margin of 2,115.11% and a negative return on equity of 100.58%. As a group, research analysts forecast that Foamix Pharmaceuticals will post -1.66 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada lifted its position in Foamix Pharmaceuticals by 76.5% in the second quarter. Royal Bank of Canada now owns 13,694 shares of the specialty pharmaceutical company’s stock worth $33,000 after buying an additional 5,937 shares during the last quarter. grace capital lifted its position in Foamix Pharmaceuticals by 86.9% in the second quarter. grace capital now owns 20,000 shares of the specialty pharmaceutical company’s stock worth $48,000 after buying an additional 9,300 shares during the last quarter. Stifel Financial Corp bought a new stake in Foamix Pharmaceuticals in the third quarter worth $54,000. Worth Venture Partners LLC lifted its position in Foamix Pharmaceuticals by 75.0% in the second quarter. Worth Venture Partners LLC now owns 23,627 shares of the specialty pharmaceutical company’s stock worth $56,000 after buying an additional 10,127 shares during the last quarter. Finally, Delek Group Ltd. lifted its position in Foamix Pharmaceuticals by 23.2% in the second quarter. Delek Group Ltd. now owns 62,437 shares of the specialty pharmaceutical company’s stock worth $145,000 after buying an additional 11,741 shares during the last quarter. Institutional investors own 47.29% of the company’s stock.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.

Read More: The mechanics of the bid-ask spread in trading

Analyst Recommendations for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.